Guru Nanak Institute of Pharmaceutical Science and Technology, Panihati, Sodepur, Kolkata 700114, West Bengal, India.
Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Int Immunopharmacol. 2021 Feb;91:107309. doi: 10.1016/j.intimp.2020.107309. Epub 2020 Dec 30.
COVID-19 is considered the most critical health pandemic of 21st century. Due to extremely high transmission rate, people are more susceptible to viral infection. COVID-19 patients having chronic type-2 asthma prevails a major risk as it may aggravate the disease and morbidities.
The present review mainly focuses on correlating the influence of COVID-19 in type-2 asthmatic patients. Besides, it delineates the treatment measures and drugs that can be used to manage mild, moderate, and severe symptoms of COVID-19 in asthmatic patients, thus preventing any exacerbation.
An in-depth research was carried out from different peer-reviewed articles till September 2020 from several renowned databases like PubMed, Frontier, MEDLINE, and related websites like WHO, CDC, MOHFW, and the information was analysed and written in a simplified manner.
The progressive results were quite conflicting as severe cases of COVID-19 shows an increase in the level of several cytokines that can augment inflammation to the bronchial tracts, worsening the asthma attacks. Contradicting to this, certain findings reveal the decrease in the severity of COVID-19 due to the elevation of T-cells in type-2 asthmatic patients, as prominent reduction of T-cell is seen in most of the COVID-19 positive patients. This helps to counteract the balance of immune responses and hence ameliorate the disease progression.
Asthmatic patients must remain cautious during the COVID-19 pandemic by maintaining all the precautions to stay safe due to limited research data. Future strategies should include a better understanding of asthmatic exacerbation and its relation to COVID-19.
COVID-19 被认为是 21 世纪最严重的健康大流行病。由于极高的传播率,人们更容易受到病毒感染。患有慢性 2 型哮喘的 COVID-19 患者是一个主要的风险因素,因为它可能使疾病恶化和增加发病率。
本综述主要关注 COVID-19 对 2 型哮喘患者的影响。此外,它还描述了可用于管理哮喘患者 COVID-19 轻症、中度和重症症状的治疗措施和药物,从而预防任何恶化。
从 2020 年 9 月之前的几个著名数据库(如 PubMed、Frontier、MEDLINE)以及世界卫生组织、疾病控制与预防中心、印度卫生部和家庭福利部等相关网站上的不同同行评议文章中进行了深入研究,并对信息进行了分析和简化。
进展结果存在很大争议,因为 COVID-19 的严重病例显示出几种细胞因子水平升高,这些细胞因子可以加重支气管炎症,使哮喘发作恶化。与此相反,某些发现表明,由于 2 型哮喘患者 T 细胞的升高,COVID-19 的严重程度降低,因为大多数 COVID-19 阳性患者的 T 细胞明显减少。这有助于对抗免疫反应的平衡,从而改善疾病进展。
由于研究数据有限,哮喘患者在 COVID-19 大流行期间必须保持警惕,采取一切预防措施以确保安全。未来的策略应包括更好地了解哮喘恶化及其与 COVID-19 的关系。